United States: In the latest work, it has been proved that troriluzole has a positive effect in avoiding early-stage Alzheimer’s disease-related brain changes in a mouse model.
Through research, the benefits of troriluzole have been shown to lower the toxic level of glutamate while preserving memory and cognitive ability.
More about the finding
This finding implies that troriluzole, if administered early, might help prevent further development of Alzheimer’s or even stop the disease in its tracks, offering new hope to patients.
However, more research work is required to establish the utility of the drug to patients at other stages of the disease.
How research was conducted?
Recently, Auburn University researchers have experimented with a new drug known as troriluzole, and it has been found to block the brain changes that can cause memory loss and other cognitive symptoms in mice that are genetically modified to have Alzheimer’s disease.
Published in the Journal of Neurochemistry, this is the first research that establishes how troriluzole impacts early changes linked to Alzheimer’s disease, opening up the possibility of a cure.
According to Dr. Miranda Reed, a Professor in the Department of Drug Discovery at Auburn University and Delivery and the study’s main researcher, “By examining how drug treatments can intervene early in the disease process, we aim to develop therapies that might prevent or even cure Alzheimer’s,” neurosciencenews.com reported.
As per Dr. Michael Gramlich, an Assistant Professor of Biophysics, “This study also highlights how scientific advancements can transform our understanding of complex diseases like Alzheimer’s.”
A Groundbreaking research
Alzheimer’s disease is a common neurological disorder that is characterized by gradual memory impairment, confusion, and subsequent development of dementia among millions.
Even now, no definitive treatment has been found despite years and decades of extensive studies. Alzheimer’s is a disease caused by the worsening amyloid plaques and tau tangles in the brain, which deter the communication of neurons.
During the first phase, values of the excitatory neurotransmitter glutamate surpass the beneficial efficacy disturbing signal transduction in the synaptic connections between neurons.
This work examined the effects of troriluzole, which is a new drug that helps mice genetically engineered to mimic the initial stages of Alzheimer’s disease and carry out normal brain functions.
The result showed that tratoriluzole not only decreased the level of toxic glutamate but also increased memory and learning in mice, therefore preserving the optimum brain function.
The researchers noted, “Our research demonstrates that by targeting synaptic activity early, we may be able to prevent or slow the progression of Alzheimer’s. This could revolutionize the way we approach treatment for this disease,” as neurosciencenews.com reported.